Distinct Characteristics of Circulating Vascular Endothelial Growth Factor-A and C Levels in Human Subjects by Wada, Hiromichi et al.
Distinct Characteristics of Circulating Vascular
Endothelial Growth Factor-A and C Levels in Human
Subjects
Hiromichi Wada
1*, Shuichi Ura
1, Shuji Kitaoka
2, Noriko Satoh-Asahara
3, Takahiro Horie
4,5, Koh Ono
1,5,
Tomohide Takaya
1,5, Rieko Takanabe-Mori
1, Masaharu Akao
1,6, Mitsuru Abe
1,6, Tatsuya Morimoto
1,7,
Toshinori Murayama
4, Masayuki Yokode
4, Masatoshi Fujita
8, Akira Shimatsu
9, Koji Hasegawa
1
1Division of Translational Research, National Hospital Organization Kyoto Medical Center, Kyoto, Japan, 2Health Evaluation Center, National Hospital Organization Kyoto
Medical Center, Kyoto, Japan, 3Division of Diabetic Research, National Hospital Organization Kyoto Medical Center, Kyoto, Japan, 4Department of Clinical Innovative
Medicine, Translational Research Center, Kyoto University Hospital, Kyoto, Japan, 5Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto
University, Kyoto, Japan, 6Department of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan, 7Division of Molecular Medicine, School of
Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan, 8Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan,
9Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan
Abstract
The mechanisms that lead from obesity to atherosclerotic disease are not fully understood. Obesity involves angiogenesis in
which vascular endothelial growth factor-A (VEGF-A) plays a key role. On the other hand, vascular endothelial growth factor-
C (VEGF-C) plays a pivotal role in lymphangiogenesis. Circulating levels of VEGF-A and VEGF-C are elevated in sera from
obese subjects. However, relationships of VEGF-C with atherosclerotic risk factors and atherosclerosis are unknown. We
determined circulating levels of VEGF-A and VEGF-C in 423 consecutive subjects not receiving any drugs at the Health
Evaluation Center. After adjusting for age and gender, VEGF-A levels were significantly and more strongly correlated with
the body mass index (BMI) and waist circumference than VEGF-C. Conversely, VEGF-C levels were significantly and more
closely correlated with metabolic (e.g., fasting plasma glucose, hemoglobin A1c, immunoreactive insulin, and the
homeostasis model assessment of insulin resistance) and lipid parameters (e.g., triglycerides, total cholesterol (TC), low-
density-lipoprotein cholesterol (LDL-C), and non-high-density-lipoprotein cholesterol (non-HDL-C)) than VEGF-A. Stepwise
regression analyses revealed that independent determinants of VEGF-A were the BMI and age, whereas strong independent
determinants of VEGF-C were age, triglycerides, and non-HDL-C. In apolipoprotein E-deficient mice fed a high-fat-diet (HFD)
or normal chow (NC) for 16 weeks, levels of VEGF-A were not significantly different between the two groups. However,
levels of VEGF-C were significantly higher in HFD mice with advanced atherosclerosis and marked hypercholesterolemia
than NC mice. Furthermore, immunohistochemistry revealed that the expression of VEGF-C in atheromatous plaque of the
aortic sinus was significantly intensified by feeding HFD compared to NC, while that of VEGF-A was not. In conclusion, these
findings demonstrate that VEGF-C, rather than VEGF-A, is closely related to dyslipidemia and atherosclerosis.
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Introduction
Obesity plays a major role in the development of dyslipidemia,
hypertension and many other sub-clinical abnormalities that
contribute to the atherosclerotic process and onset of cardiovas-
cular events [1,2]. However, the mechanisms that lead from
obesity to atherosclerosis and cardiovascular events are not fully
understood.
It is widely accepted that adipose tissue development involves
adipogenesis and angiogenesis [3]. Vascular endothelial growth
factor-A (VEGF-A) signaling through VEGF receptor-2 (VEGFR-
2) is the main angiogenic pathway [4]. It has been reported that
VEGF-A accounts for much of the angiogenic activity of adipose
tissue [5]. In addition, the administration of anti-VEGF-A
antibody inhibited not only angiogenesis but also adipogenesis,
which provides direct evidence that angiogenesis is essential for
adipogenesis in obesity [6]. Circulating levels of VEGF-A are
elevated in overweight and obese subjects [7]. Levels of VEGF-A is
positively correlated with body mass index (BMI), and this
correlation is apparently disconnected from insulin sensitivity
[8]. However, a population-based cross-sectional study revealed
that circulating VEGF-A levels have only a minor impact on the
development of atherosclerosis [9].
Vascular endothelial growth factor-C (VEGF-C), a homologue
of VEGF-A, plays a key role in lymphangiogenesis via VEGF
receptor-3 (VEGFR-3). Deletion of Vegfc in mice leads to a
complete absence of lymph vessels and embryonic lethality [10].
Overexpression of VEGF-C in the skin of transgenic mice induces
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clinical setting, serum levels of VEGF-C are increased in patients
with some cancers and are suggested to be associated with lymph
node and distant metastases, as well as a poor prognosis [12–16].
Serum levels of VEGF-C are also elevated in overweight and
obese subjects [7]. However, precise relationships of serum VEGF-
C levels with clinical, lipid, and metabolic profiles and athero-
sclerosis are unknown.
Therefore, in the present study, we examined: 1) circulating
levels of VEGF-A and VEGF-C in subjects not receiving any
medications and examined their association with clinical, lipid,
and metabolic parameters in comparison with those of VEGF-A,
and 2) serum levels of VEGF-A and VEGF-C as well as their
expression levels in the aortic sinus including atheromatous plaque
in apolipoprotein E (apoE)-deficient mice fed a high-fat-diet in
comparison with those fed normal chow.
Methods
Subjects
A cross-sectional study was carried out during a specified period
from April 2008 to March 2011. A total of 423 Japanese subjects
not receiving any medications were recruited in the Health
Evaluation Center of Kyoto Medical Center. All participants
provided written informed consent. The study protocol was
approved by the Institutional Ethics Committee of Kyoto Medical
Center.
Data collection
Details are described elsewhere [17]. Briefly, blood was taken
from the antecubital vein from 9 to 10 in the morning after a 12-h
fast. Plasma levels of glucose and hemoglobin A1c (HbA1c), and
serum levels of triglycerides, high-density-lipoprotein cholesterol
(HDL-C), total cholesterol (TC), and low-density-lipoprotein
cholesterol (LDL-C) were measured according to standard
procedures. Non-high-density-lipoprotein cholesterol (nonHDL-
C) was calculated employing the following formula: Non-HDL-C
=T C 2HDL-C. Immunoreactive insulin was measured using an
enzyme immunoassay with a commercially available kit (Tosoh,
Tokyo, Japan). The serum and plasma obtained were divided into
aliquots and stored at 280uC until being assayed for VEGF-A and
VEGF-C. Their serum (VEGF-C) or plasma (VEGF-A) concen-
trations were measured employing specific, commercially avail-
able, enzyme-linked immunosorbent assay (ELISA) kits according
to the manufacturers’ instructions (Quantikine, R&D Systems,
Minneapolis, Minnesota, USA). The sensitivities of the assays for
VEGF-C and VEGF-A were 4.6 and 5.0 pg/ml, respectively.
Inter-/intra-assay coefficients of variation of ELISA for VEGF-C
and VEGF-A were 7.2/3.5 and 7.0/4.5%, respectively. These
assays were performed by an investigator blinded to the sources of
the samples.
Experimental atherosclerosis
ApoE-deficient mice (129Ola 6 C57BL/6 mixed background)
were a generous gift from Edward M. Rubin (University of
California at Berkeley, Berkeley, California, USA) [18]. They were
mated with C57BL/6 mice to produce F1 hybrids. The F1 apo
E+/2 mice were then backcrossed with C57BL/6 mice for 10
generations. Mice homogeneous for the apoE-null allele on a
C57BL/6 background were subsequently generated. Male mice
were used in the subsequent experiments. They were kept in a
temperature-controlled facility under a 12-h light–dark cycle with
free access to food and water. After being weaned at 4 weeks of
age, mice were fed a normal chow diet (NC, Oriental Yeast Co.,
Ltd., Tokyo, Japan) until 6 weeks of age, when they were divided
into an NC group and a high-fat-diet (HFD) group containing
40% fat and 0.15% cholesterol (Oriental Yeast). The experimental
protocols were approved by the Ethics Committee for Animal
Experiments of Kyoto University.
Serum samples from mice
At the age of 22 weeks, blood was drawn from the inferior vena
cava of anesthetized mice and serum was separated by
centrifugation at 4uC and stored at 280uC. Serum levels of total
cholesterol, LDL-C, HDL-C, and triglycerides were measured
using the standard methods (Nagahama Life Science Laboratory,
Shiga, Japan). Those of VEGF-A and VEGF-C were measured
employing specific ELISA kits according to the manufacturers’
instructions (Quantikine, R&D Systems, Minneapolis, Minnesota,
USA for VEGF-A, Cusabio Biotech Co., Ltd., Newark, Delaware,
USA for VEGF-C).
Preparation of tissue and quantification of
atherosclerosis in mice
After anesthesia, the mice were euthanized at 22 weeks of age,
and their proximal aortas were excised, fixed in 4% paraformal-
dehyde (Nacalai Tesque, Inc, Kyoto, Japan), washed in sucrose,
embedded in OCT compound (Tissue-Tek, Sakura Finetechnical
Co., Ltd., Tokyo, Japan), frozen on dry ice, and then stored at
280uC until sectioning. The OCT-embedded aortas were
sectioned with a cryostat, and 6-mm sections were obtained
sequentially, beginning at the aortic valve. Eight sections obtained
every 24 mm from the aortic sinus were stained with oil red O and
used for quantification of the lesion areas. The total and
atherosclerotic areas of each aorta were measured with image
analysis (ImageJ), and the ratio of the atherosclerotic area to the
total area was calculated.
Immunohistochemistry
The frozen sections were washed in phosphate-buffered saline
(PBS) and endogenous peroxidase activity was blocked by 0.3%
H2O2 in methyl alcohol for 30 min. The sections were washed in
PBS (6 times, 5 each min) and mounted with 1% normal goat
serum in PBS for 30 min. Subsequently, primary antibody (rat
anti-mouse VEGF-A antibody (1:100), Biolegend, San Diego
California, USA; rabbit anti-rat VEGF-C antibody (1:200) (also
reacts with mouse and human VEGF-C), Abcam plc., Tokyo,
Japan) was applied overnight at 4uC. After washing in PBS (6
times, 5 min), they were incubated with peroxidase-labeled
secondary antibody polymer (Histofine Simple Stain Mouse
MAX-PO (Rat or Rabbit), Nichirei Biosciences Inc., Tokyo,
Japan) for 30 min. After washing in PBS (6 times, 5 min), a
coloring reaction was carried out with diaminobenzidine (Wako
Pure Chemical Industries, Osaka, Japan) and nuclei were
counterstained with hematoxylin. The numbers of VEGF-A-
positive and VEGF-C-positive cells were counted in a cross-section
of the aortic sinus including atheromatous plaque in each mouse.
Statistical analysis
All statistical analyses were performed using Stat View version
5.0 for Windows (SAS Institute Inc., Cary, North Carolina, USA.).
The Mann-Whitney U test was employed for comparisons of
values between the two groups. Relationships between either of
VEGF-A or VEGF-C and other parameters were analyzed by age-
and gender-adjusted correlations and a stepwise linear regression.
Stepwise regression was performed in a forward direction with F
for the entry set to 4. Because triglycerides, fasting glucose,
VEGF-C and Dyslipidemia
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resistance (HOMA-IR), adiponectin, high-sensitivity C-reactive
protein (hsCRP), and VEGF-A were normally distributed after
logarithmic transformation, the logarithms of these parameters
were used in the analyses. Data are expressed as the means 6 SD
or the medians and inter-quartile ranges, as appropriate. Values of
P,0.05 were considered significant.
Results
Differential Association of Circulating Levels of VEGF-C
and VEGF-A with Clinical, Lipid, and Metabolic
Parameters
The clinical characteristics of subjects are shown in Table 1.
The prevalence of obesity (defined as a body mass index .25 kg/
m
2), hypertension (defined as systolic blood pressure .=140 or
diastolic blood pressure .=90 mmHg), dyslipidemia (defined as
LDL-C .=140 mg/dL, HDL-C,40 mg/dL, or triglycerides
.=150 mg/dL) was 26, 13, and 42%, respectively. That of
metabolic syndrome (defined as the presence of any 3 of the
following 5 criteria: 1) increased waist circumference (.=85cm
in men or .=90 cm in women), 2) elevated triglycerides
(.=150 mg/dL), 3) reduced concentration of high-density
lipoprotein cholesterol (HDL-C) (,40 mg/dL in men or
,50 mg/dL in women), 4) elevated blood pressure (systolic blood
pressure .=130 or diastolic blood pressure .=85 mmHg), and
5) elevated fasting glucose (.=100 mg/dL)) was 16%. Thus, they
were not necessarily healthy, but had yet to receive any
medications. Distribution of circulating levels of VEGF-A were
skewed, while levels of VEGF-C were almost normally distributed.
Therefore, values of VEGF-A levels were log-transformed for
subsequent analyses.
Then, we examined the association of circulating VEGF-A and
VEGF-C levels with clinical, lipid, and metabolic parameters after
adjusting for age and gender (Table 2). Levels of VEGF-A were
significantly and more strongly correlated with the body mass
index, waist circumference, and adiponectin levels than VEGF-C.
Conversely, levels of VEGF-C were significantly and more closely
correlated with lipid (e.g., triglyceride, TC, LDL-C, and non-
HDL-C) and metabolic parameters (e.g., fasting plasma glucose,
hemoglobin A1c, immunoreactive insulin, and HOMA-IR).
Independent Determinants of VEGF-A and VEGF-C levels
To identify independent determinants of VEGF-A and VEGF-
C levels, stepwise multiple regression analyses were performed.
The body mass index and age were independent determinants of
VEGF-A levels (Table 3). In contrast, independent determinants of
VEGF-C were age, triglycerides, non-HDL-C, and hemoglobin
A1c (Table 3). These findings suggest that VEGF-A is associated
with overweightness itself, whereas VEGF-C is closely associated
with lipid and metabolic disorders. The correlation between
VEGF-A and the body mass index and correlations of VEGF-C
with triglycerides and non-HDL-C are shown in Figures 1A, B,
and C, respectively.
Serum and expression levels in atheromatous plaque of
VEGF-A and VEGF-C in apoE-deficient mice
To examine the relationship between VEGF-C and atheroscle-
rosis with dyslipidemia, apoE-deficient mice, one of the most
popular animal models of dyslipidemia and atherosclerosis, were
fed a HFD (n=3) or NC (n=3) for 16 weeks. Thereafter, body
weight (4261 vs. 3161 g, respectively, P,0.05) and serum levels
of total cholesterol (11376237 vs. 6856125 mg/dL, respectively,
P,0.05) and LDL-C (393678 vs. 162621 mg/dL, respectively,
P,0.05), but not HDL-C (2865 vs. 2063 mg/dL, respectively)
and triglycerides (122637 vs. 127660 mg/dL, respectively), were
significantly higher in the HFD than NC group. Atheromatous
plaque in proximal aortas quantified by oil red O staining was
markedly greater in the HFD than NC group (Figure 2A).
Immunohistochemistry revealed that the number of VEGF-C-
positive cells, but not that of VEGF-A, was significantly greater in
HFD with advanced atherosclerosis than NC mice with minimal
atherosclerosis (Figures 2B–F). Interestingly, serum levels of
VEGF-C, but not those of VEGF-A, were significantly higher in
HFD than NC mice (Figures 2G and H). These findings indicate
that VEGF-C, rather than VEGF-A, is closely related to advanced
atherosclerosis with marked hypercholesterolemia induced by
HFD in apoE-deficient mice.
Discussion
The present study demonstrated that circulating levels of
VEGF-C are closely associated with dyslipidemia in marked
contrast to the fact that the strongest independent determinants of
VEGF-A was the body mass index. These findings suggest that
VEGF-A increases in association with overweightness itself;
however, VEGF-C increases in association with dyslipidemia
rather than overweightness per se. To our knowledge, this is the
first study to report an association between VEGF-C and
dyslipidemia.
Loebig et al. demonstrated that a positive correlation between
VEGF-A and body mass index and that the relationship is
Table 1. Demographic Data of Human Subjects.
Number of patients, n 423
(Male/Female, n) (281/142)
Age, y 4569
Male gender,% 66647
Body mass index, kg/m
2 22.963.1
Waist circumference, cm 8369
Systolic blood pressure, mmHg 117616
Diastolic blood pressure, mmHg 74611
Fasting plasma glucose, mg/dL 95 [90–101]
Hemoglobin A1c,% 5.1960.29
Immunoreactive insulin, mU/L 5.0 [4.0–8.0]
HOMA-IR 1.3 [0.8–1.8]
Triglycerides, mg/dL 96 [66–138]
HDL-C, mg/dL 69618
Total cholesterol, mg/dL 209632
LDL-C, mg/dL 126631
Non-HDL-C, mg/dL 139636
hsCRP, mg/mL 0.15 [0.10–0.30]
Adiponectin, mg/mL 7.7 [5.7–10.9]
VEGF-A, pg/mL 278 [163–434]
VEGF-C, pg/mL 613561409
Data are expressed as the mean 6 SD, median [25–75 percentile], or number of
patients. HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density
lipoprotein cholesterol; Non-HDL-C: non-high-density lipoprotein cholesterol;
HOMA-IR: homeostasis model assessment of insulin resistance; hsCRP: high-
sensitivity C-reactive protein; VEGF-A: vascular endothelial growth factor-A,
VEGF-C: vascular endothelial growth factor-C.
doi:10.1371/journal.pone.0029351.t001
VEGF-C and Dyslipidemia
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et al. have shown that circulating VEGF-A levels have only a
minor impact on the development of atherosclerosis [9]. However,
VEGF-C is tightly associated with dyslipidemia, a potent risk
factor as well as a therapeutic target of cardiovascular disease. In
addition, we demonstrated that serum levels and expression levels
in atheromatous plaque of VEGF-C, but not VEGF-A, were
significantly increased in HFD-fed apoE-deficient mice with
advanced atherosclerosis, suggesting that VEGF-C was more
closely related to atherosclerosis with dyslipidemia than VEGF-A.
Table 2. Correlations of Vascular Endothelial Growth Factor-A
(VEGF-A) and Vascular Endothelial Growth Factor–C (VEGF-C)
with Other Parameters.
VEGF-A VEGF-C
rP r P
Body mass index , kg/m
2 0.21 ,0.0001 0.13 0.008
Waist circumference, cm 0.19 0.0001 0.13 0.007
Systolic blood pressure , mmHg 0.09 0.06 0.08 0.09
Diastolic blood pressure , mmHg 0.16 0.001 0.08 0.09
Fasting plasma glucose, mg/dL
a 0.09 0.06 0.11 0.03
Hemoglobin A1c,% 0.11 0.02 0.13 0.007
Immunoreactive insulin, mU/L
a 0.08 0.1 0.17 0.0006
HOMA-IR
a 0.09 0.07 0.18 0.0003
Triglycerides, mg/dL
a 0.10 0.04 0.23 ,0.0001
HDL-C, mg/dL 20.09 0.054 20.08 0.1
Total cholesterol, mg/dL 0.07 0.2 0.18 0.0002
LDL-C, mg/dL 0.07 0.1 0.17 0.0004
Non-HDL-C, mg/dL 0.11 0.03 0.20 ,0.0001
hsCRP, ng/mL
a 0.10 0.04 0.12 0.01
Adiponectin, mg/mL
a 20.14 0.003 20.08 0.1
VEGF-A, pg/mL
a - - 0.11 0.03
VEGF-C, pg/mL 0.11 0.03 - -
Abbreviations used in this table are the same as in Table 1.
aLog-transformed to obtain normal distributions. Values were adjusted for age
and gender.
doi:10.1371/journal.pone.0029351.t002
Table 3. Independent determinants of VEGF-A and VEGF-C
levels.
VEGF-A VEGF-C
b SEM F b SEM F
Body mass index, kg/m
2 0.16 3.4 11
Age, y 0.11 0.1 5 20.18 8.1 13.1
Triglycerides, mg/dL
a 0.14 1.3 6.2
Non-HDL-C, mg/dL 0.14 2.2 5.7
Hemoglobin A1c, % 0.11 251 4.3
Abbreviations used in this table are the same as in Table 1. These models
include data on the age, a male gender, body mass index, waist circumference,
systolic and diastolic blood pressures, fasting plasma glucose, hemoglobin A1c,
immunoreactive insulin, HOMA-IR, triglycerides, HDL-C, total cholesterol, LDL-C,
non-HDL-C, hsCRP, and adiponectin.
doi:10.1371/journal.pone.0029351.t003
Figure 1. The correlation of circulating vascular endothelial
growth factor-A (VEGF-A) or C (VEGF-C) levels with their
independent determinants. A. The correlation between circulating
VEGF-A levels and the body mass index. B. The correlation between
those of VEGF-C and those of triglycerides. C. The correlation between
those of VEGF-C and those of non-high-density-lipoprotein cholesterol
(nonHDL-C).
doi:10.1371/journal.pone.0029351.g001
VEGF-C and Dyslipidemia
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and future cardiovascular events than VEGF-A in humans.
VEGF-C induces lymphangiogenesis, which is involved in the
draining of interstitial fluid and in immune function and
inflammation [11]. It has been reported that VEGF-C levels are
elevated in patients with refractory hypertension, and that VEGF-
C/VEGFR-3 signaling in macrophages is a major determinant of
the extracellular volume and blood pressure homeostasis [19]. The
trapping of VEGF-C by soluble VEGF receptor-3 blocks VEGF-C
signaling, and elevates the blood pressure in response to a high-
salt-diet [19]. Thus, VEGF-C seems to be up-regulated to
compensate for salt-diet-induced hypertension. Similarly, VEGF-
C might be up-regulated to compensate for the development and
progression of atheromatous plaque by draining lipid and/or
inflammatory cells in response to dyslipidemia. However, further
investigation is required regarding this matter.
While lymphatic vessels are rare in the atherosclerotic intima
[20], membrane-bound VEGF receptor-2 (VEGFR-2) is up-
regulated in atherosclerotic lesion in human coronary arteries
[21]. A recent report suggested that a soluble form of VEGFR-2
(sVEGFR-2) inhibits lymphangiogenesis by blocking the VEGF-C
function, and that the tissue-specific loss of the sVEGFR-2 gene
induces lymphatic invasion of the normally alymphatic cornea and
hyperplasia of skin lymphatics without affecting the blood
vasculature [22]. These findings suggest that naturally occurring
sVEGFR-2 acts as a molecular uncoupler of blood and lymphatic
vessels [22]. We recently demonstrated that serum levels of
sVEGFR-2 are increased in sera from subjects with metabolic
syndrome in association with insulin resistance [17]. Thus, it is of
interest to elucidate the interaction between VEGF-C and
sVEGFR-2 in the regulation of lymphangiogenesis at vessel walls
and in the progression of atherosclerosis.
Several study limitations should be considered. First, the present
study was limited due to its moderate sample size. However, all the
study participants did not receive any medications including statins
or renin-angiotensin-system inhibitors, which could substantially
affect serum levels of angiogenesis-related factors. Thus, the
relationships between these biomarkers and established risk factors
in this study are physiological. Second, this human study was
cross-sectional, and, thus, the results cannot help answer the
question of whether elevations of VEGF-C are merely conse-
quences of metabolic abnormality or causes of future cardiovas-
cular events in these subjects. Third, to elucidate its prognostic
significance, the direct relationship of VEGF-C with cardiovascu-
lar events and/or atherosclerosis in patients should be investigated
in future studies. Finally, at present, the sources of endogenous
VEGF-C in human sera, and the relationships of their levels with
cardiovascular lymphangiogenic activity are unclear.
Nevertheless, the present study first demonstrates that circulat-
ing levels of VEGF-C are closely associated with dyslipidemia and
atherosclerosis. Future investigations are warranted to determine
the precise role of lymphangiogenesis in the pathogenesis of
atherosclerosis, and the clinical utility of serum VEGF-C levels.
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